This review provides a concise overview of current possibilities for prophylaxis and therapy of VTE events in cancer patients.
Answers are grounded in this paper and cite their sources.
Supports clinician awareness of VTE options in cancer; leaves open gaps for prospective trials.
Cancer is a highly thrombophilic entity leading to a high rate of symptomatic and even asymptomatic venous thromboembolic (VTE) events in patients suffering from malignant disease. As VTE events have impact on survival and can be reduced significantly by anticoagulant treatment, guidelines on prophylaxis of these events by means of anticoagulation exist from various societies. Purpose of this review is to give a concise overview of current possibilities for prophylaxis and also for the therapy of VTE events in cancer patients.
No takes yet. Share an insight, caveat, or question.
Thomas Gary (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: